A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma von Reckamp, Karen L., Melnikova, Vladislava O., Karlovich, Chris, Sequist, Lecia V., Camidge, D. Ross, Wakelee, Heather, Perol, Maurice, Oxnard, Geoffrey R., Kosco, Karena, Croucher, Peter, Samuelsz, Errin, Vibat, Cecile Rose, Guerrero, Shiloh, Geis, Jennifer, Berz, David, Mann, Elaina, Matheny, Shannon, Rolfe, Lindsey, Raponi, Mitch, Erlander, Mark G., Gadgeel, Shirish

Volltext

Cryopreservation of hematopoietic stem cells von Berz, David, McCormack, Elise M., Winer, Eric S., Colvin, Gerald A., Quesenberry, Peter J.

Volltext

Anticancer activity of 2'-hydroxyflavanone towards lung cancer von Awasthi, Sanjay, Singhal, Sharad S, Singhal, Jyotsana, Nagaprashantha, Lokesh, Li, Hongzhi, Yuan, Yate-Ching, Liu, Zheng, Berz, David, Igid, Henry, Green, William C, Tijani, Lukman, Tonk, Vijay, Rajan, Aditya, Awasthi, Yogesh, Singh, Sharda P

Volltext

748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors von Sanborn, Rachel E, Furqan, Muhammad, Laux, Doug, Sharma, Manish, Olson, Daniel, Berz, David, Hauke, Ralph J, Massarelli, Erminia, Steuer, Conor, Davis, Elizabeth, Iams, Wade T, Thompson, Jonathan, Hamm, John, Andrianov, Vasily, O’Neill, Brianne, Durana, Yaiza Diaz De, Tolcher, Anthony W

Volltext

742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors von Park, Jong Chul, Berz, David, Sharma, Manish, Massarelli, Erminia, Hauke, Ralph J, Tsai, Frank Yung-Chin, Hong, David, Akhave, Neal, Call, Justin A, Carlisle, Jennifer, Sanborn, Rachel E, Haas, Naomi B, Hamm, John, Ross Camidge, D, Spira, Alexander I, Andrianov, Vasily, O’Neill, Brianne, Kinkead, Heather, Tolcher, Anthony W

Volltext

Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer von Berz, David, Raymond, Victoria M, Garst, Jordan H, Erlander, Mark G

Volltext

A pilot study on the anticancer effects of novel candidate agent COH-SR4 in lung cancer von Berz, David

Volltext

The neoadjuvant therapy of colorectal hepatic metastases and the role of biologic sensitizing and resistance factors von Wanebo, Harold J., Berz, David

Volltext

Left sided inferior vena cava duplication and venous thromboembolism: case report and review of literature von Milani, Cannon, Constantinou, Maria, Berz, David, Butera, James N, Colvin, Gerald A

Volltext

A novel three-biomarker signature (CA-62, CEA, CYFRA 21-1) and early-stage NSC lung cancer detection von Tcherkassova, Janneta, Tsurkan, Sergei, Prostyakova, Anna, Klinski, Evgueni, Sekacheva, Marina, Boroda, Alexander, Moro, Ricardo, Berz, David

Volltext

ACCLAIM-1 dose escalation: Determination of quaratusugene ozeplasmid and osimertinib recommended phase 2 dose (RP2D) von Berz, David, Jotte, Robert M., Pachipala, Krishna Kishore, Spira, Alexander I., Berger, Mark S.

Volltext

Targeting the growth factors and angiogenesis pathways: Small molecules in solid tumors von Berz, David, Wanebo, Harold

Volltext

Survival of Patients with Squamous Cell Malignancies of the Upper Urinary Tract von Berz, David, Rizack, Tina, Weitzen, Sherry, Mega, Anthony, Renzulli, Joseph, Colvin, Gerald

Volltext

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial von Yang, James Chih-Hsin, Camidge, D. Ross, Yang, Cheng-Ta, Zhou, Jianying, Guo, Renhua, Chiu, Chao-Hua, Chang, Gee-Chen, Shiah, Her-Shyong, Chen, Yuan, Wang, Chin-Chou, Berz, David, Su, Wu-Chou, Yang, Nong, Wang, Ziping, Fang, Jian, Chen, Jianhua, Nikolinakos, Petros, Lu, You, Pan, Hongming, Maniam, Ajit, Bazhenova, Lyudmila, Shirai, Keisuke, Jahanzeb, Mohammad, Willis, Maurice, Masood, Nehal, Chowhan, Naveed, Hsia, Te-Chun, Jian, Hong, Lu, Shun

Volltext

Pneumonectomy After Neoadjuvant Chemotherapy and Radiation for Advanced-Stage Lung Cancer von Ng, Thomas, Birnbaum, Ariel E., Fontaine, Jacques P., Berz, David, Safran, Howard P., Dipetrillo, Thomas A.

Volltext

Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Up... von Heymach, John, Opdam, Frans, Barve, Minal A., Tu, Hai-Yan, Wu, Yi-Long, Berz, David, Gibson, Neil, Sadrolhefazi, Behbood, Serra, Josep, Yoh, Kiyotaka, Yamamoto, Noboru

Volltext

Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer von Rosen, Ezra, Sharma, Manish, Berz, David, Caswell-Jin, Jennifer Lee, Spira, Alexander I., Fulgar, Georgina A., Densel, Mark, Rana, Nawaid, Sperry, Samuel, Warner, Douglas, Meric-Bernstam, Funda

Volltext

OA01.01 Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors von Heymach, John, Yamamoto, Noboru, Opdam, Frans, Barve, Minal, Tu, Hai-Yan, Wu, Yi-Long, Schroeter, Lukas, Sadrolhefazi, Behbood, Serra, Josep, Yoh, Kiyotaka, Berz, David

Volltext

Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2) von Spigel, David, Jotte, Robert, Nemunaitis, John, Shum, Merrill, Schneider, Jeffrey, Goldschmidt, Jerome, Eisenstein, Jennifer, Berz, David, Seneviratne, Lasika, Socoteanu, Matei, Bhanderi, Viralkumar, Konduri, Kartik, Xia, Meng, Wang, Hong, Hozak, Rebecca R., Gueorguieva, Ivelina, Ferry, David, Gandhi, Leena, Chao, Bo H., Rybkin, Igor

Volltext

Cremophor-Induced Lupus Erythematosus-Like Reaction with Taxol Administration: A Case Report and Review of the Literature von Pham, Anthony Q., Berz, David, Karwan, Patricia, Colvin, Gerald A.

Volltext